TNDM - タンデム・ダイアベティス・ケア （Tandem Diabetes Care Inc.） タンデム・ダイアベティス・ケアTNDMのチャート
TNDMの企業情報
| symbol | TNDM |
|---|---|
| 会社名 | Tandem Diabetes Care Inc （タンデム・ダイアベティス・ケア） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 タンデム・ダイアベティス・ケア（Tandem Diabetes Care Inc.）はインスリン依存性糖尿病を有する人々に製品の設計・開発・商業化を提供する医療機器会社である。同社は技術プラットフォーム及び消費者中心のアプローチに基づいて同社の代表的製品である「t:slim」インスリン送達システムまたは「t:slim」を設計・商業化する。同社の技術プラットフォームはシリンジとプランジャー機構に依頼するよりも、ポンプのカートリッジ内で柔軟性のあるバッグからインスリンを描く小型化ポンプ機構であるマイクロ送達技術を特徴とする。同社はまた所望のユーザーに同社の機器を最適化しようとする同社の設計・開発プロセスに人的要因の研究を応用し、これによってユーザーが所望の環境で機器を正常に操作することを可能にする。 タンデム・ダイアベティス・ケアは米国の医療機器メ―カ―。主に、インスリン依存性糖尿病患者向けの製品の設計、開発、商業化に従事。主力製品は、「t: slim」インスリン・デリバリ―・システム。技術プラットフォ―ムには、特許を取得している小型ポンプメカニズムのマイクロ・デリバリ―・テクノロジ―がある。本社はカリフォルニア州。 Tandem Diabetes Care, Inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem's flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California. |
| 本社所在地 | 11045 Roselle Street San Diego CA 92121 USA |
| 代表者氏名 | Dick P. Allen ディックP.アレン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 858-366-6900 |
| 設立年月日 | 38718 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | － |
| url | www.tandemdiabetes.com |
| nasdaq_url | https://www.nasdaq.com/symbol/tndm |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -45.48400 |
| 終値（lastsale） | 34.725 |
| 時価総額（marketcap） | 1987146597.9 |
| 時価総額 | 時価総額（百万ドル） 1946.893 |
| 売上高 | 売上高（百万ドル） 128.70100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1937.488 |
| 当期純利益 | 当期純利益（百万ドル） -171.09300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Tandem Diabetes Care Inc revenues increased 52% to $61.4M. Net loss increased from $45.6M to $92.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 31% to $11.9M (expense) Other Selling general and administ. increase of 5% to $40.5M (expense). |
TNDMのテクニカル分析
TNDMのニュース
Pacer Advisors Inc. Acquires 5,062 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) 2023/05/05 09:10:41 The AM Reporter
Pacer Advisors Inc. increased its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating) by 69.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,328 shares of the medical device company’s stock after buying an additional 5,062 shares […]
Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Down on Analyst Downgrade 2023/05/05 05:44:41 The AM Reporter
Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating)’s share price gapped down prior to trading on Thursday after Stifel Nicolaus lowered their price target on the stock from $45.00 to $40.00. The stock had previously closed at $39.95, but opened at $35.18. Tandem Diabetes Care shares last traded at $36.51, with a volume of 329,418 […]
Why Tandem Diabetes Care Shares Are Falling Today 2023/05/04 14:03:55 Benzinga
Tandem Diabetes Care Inc (NASDAQ: TNDM ) shares are down Thursday morning as its Q1 results missed Street expectations. TNDM reported Q1 FY23 sales of $169.39 million , missing the consensus of $170.23 million. The automated insulin delivery technology maker posted adjusted losses of $(40.4) million, compared to a loss of $(14.7) million a year ago. Adjusted EPS loss of $(0.63) missed the Street view of $(0.52). The worldwide installed base … Full story available on Benzinga.com
Tandem Diabetes Care, Inc. (TNDM) Q1 2023 Earnings Call Transcript 2023/05/04 03:42:03 Seeking Alpha
Tandem Diabetes Care, Inc. (NASDAQ:NASDAQ:TNDM) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ETCompany ParticipantsSusan Morrison - Executive Vice President and Chief Administrative…
Recap: Tandem Diabetes Care Q1 Earnings 2023/05/03 20:36:15 Benzinga
Tandem Diabetes Care (NASDAQ: TNDM ) reported its Q1 earnings results on Wednesday, May 3, 2023 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Tandem Diabetes Care missed estimated earnings by 21.15%, reporting an EPS of $-0.63 versus … Full story available on Benzinga.com
Tandem Diabetes Care PT Lowered to $71 at Barclays 2023/02/24 11:43:15 Investing.com
https://www.investing.com/news/pro/tandem-diabetes-care-pt-lowered-to-71-at-barclays-432SI-3013601
Tandem Diabetes Care Shares Fell Post Q4 Results; Guides Within Estimates 2023/02/23 13:55:15 Benzinga
Tandem Diabetes Care Inc (NASDAQ: TNDM ) reported Q4 FY22 sales of $220.50 million , missing the consensus of $221.83 million. The automated insulin delivery technology maker posted adjusted losses of $(0.46) million, compared to an income of $10.81 million a year ago. Tandem … Full story available on Benzinga.com
Tandem Diabetes Care PT Lowered to $40 at Baird 2023/02/23 11:39:08 Investing.com
https://www.investing.com/news/pro/tandem-diabetes-care-pt-lowered-to-40-at-baird-432SI-3011879
Tandem Diabetes Care PT Lowered to $50 at Piper Sandler 2023/02/23 11:19:26 Investing.com
https://www.investing.com/news/pro/tandem-diabetes-care-pt-lowered-to-50-at-piper-sandler-432SI-3011822
Tandem Diabetes Care, Inc. (TNDM) Q4 2022 Earnings Call Transcript 2023/02/23 00:41:13 Seeking Alpha
Tandem Diabetes Care, Inc. (NASDAQ:NASDAQ:TNDM) Q4 2022 Earnings Conference Call February 22, 2023 4:30 PM ETCompany ParticipantsSusan Morrison - EVP & Chief Administrative OfficerJohn…
Investing in Tandem Diabetes Care Inc. (TNDM) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/12/22 13:32:00 US Post News
As of Wednesday, Tandem Diabetes Care Inc.’s (NASDAQ:TNDM) stock closed at $42.52, up from $41.54 the previous day. While Tandem Diabetes Care Inc. has overperformed by 2.36%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TNDM fell by -71.69%, with highs and lows ranging from $155.86 […]
Tandem Diabetes Acquires Swiss Based Insulin Patch Pump Developer 2022/12/13 19:27:14 Benzinga
Tandem Diabetes Care Inc (NASDAQ: TNDM ) has agreed to acquire AMF Medical SA , the privately held Swiss developer of the investigational Sigi Patch Pump. It is designed to be an ergonomic, rechargeable patch pump that reduces the burden of managing diabetes through … Full story available on Benzinga.com
Tandem Diabetes Care to acquire patch pump maker AMF Medical 2022/12/13 14:44:27 Drug Delivery Business
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it acquired AMF Medical, maker of the Sigi patch pump for insulin delivery. Switzerland-based AMF Medical currently develops the Sigi patch pump and does not offer it commercially. The system received FDA breakthrough device designation just over one year ago. AMF Medical designed Sigi as an ergonomic, rechargeable […] The post Tandem Diabetes Care to acquire patch pump maker AMF Medical appeared first on Drug Delivery Business .
Tandem Diabetes Care to acquire Swiss insulin patch pump developer 2022/12/13 11:44:03 Seeking Alpha
Tandem Diabetes Care (TNDM) has agreed to acquire Swiss insulin patch pump developer, AMF Medical for CHF 62.4M in cash due at closing.The agreement covers a previous strategic…
Tandem Diabetes to acquire Swiss insulin pump maker AMF Medical 2022/12/13 11:40:19 MarketWatch
Tandem Diabetes Care Inc. , an insulin delivery and diabetes technology company, said Tuesday it has entered a definitive agreement to acquire AMF Medical SA, a Swiss privately held maker of the Sigi Patch Pump. The pump is currently under development and is not commercially available. "It is designed to be an ergonomic, rechargeable patch pump that reduces the burden of managing diabetes through its use of pre-filled insulin cartridges and its compatibility with automated insulin delivery technology," the San Diego-based Tandem said in a statement. Tandem will pay 62.4 million Swiss francs ($66.4 million) upon closing, as well as a previous investment of 8 million Swiss francs, and up to 129.6 million francs of earnout payments upon achievement of certain milestones. The deal is expected to close in January. Tandem stock was not active premarket, but has fallen 71% in the year to date, while the S&P 500 has fallen 16%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.